The prostate cancer market is roaring ahead thanks to Johnson & Johnson's
Approval of the drug, which will be marketed as Zytiga, came considerably earlier than its PDUFA date of June 20. Ironically -- or perhaps a sign the agency loves prostate cancer drugs -- sanofi-aventis' Jevtana, which Zytiga will compete with, had a similar experience. Both drugs are approved for prostate cancer patients that have failed a round of sanofi's Taxotere.
Johnson & Johnson's, Dendreon's, and Sanofi's biggest problem might not be competing among themselves, but the plethora of prostate cancer drugs in development. Medivation's
Roaring ahead tends to be good for patients, but not so much for those already on the market.
Johnson & Johnson is a Motley Fool Inside Value selection. Exelixis is a Motley Fool Rule Breakers recommendation. Teva Pharmaceutical Industries is a Motley Fool Global Gains choice. Johnson & Johnson is a Motley Fool Income Investor selection. Motley Fool Options has recommended a diagonal call position on Johnson & Johnson. The Fool owns shares of Exelixis, Johnson & Johnson, and Teva Pharmaceutical Industries. Alpha Newsletter Account LLC owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.